Stage IV Non-Small Cell Lung Cancer Clinical Trial
Official title:
Addition of the Gamma-Secretase Inhibitor RO4929097 to Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling pathway inhibitor RO4929097 (RO4929097) and erlotinib hydrochloride when given together in treating patients with non-small cell lung cancer that is stage IV or has come back. RO4929097 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVES:
I. To define the maximum-tolerated dose (MTD) and toxicity of RO4929097 combined with
erlotinib (erlotinib hydrochloride) in patients with advanced non-small cell lung cancer
(NSCLC). (Dose escalation portion) II. To assess whether the probability of detectable tumor
shrinkage or response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
correlates with pre-therapy immunohistochemistry (IHC) and reverse phase protein array
(RPPA) expression of Notch 1, 2, 3, and 4. (Dose escalation portion) III. A preliminary,
exploratory assessment will be performed with respect to percent tumor shrinkage and the
probability of response over the first 2 cycles of therapy. (Expansion cohort) IV. A
preliminary, exploratory assessment will be performed with respect to change in tumor
immunohistochemistry (IHC) scores and reverse phase protein array (RPPA) expression for
Notch 1, 2, 3, and 4 over the first 2 cycles of erlotinib. (Expansion cohort)
SECONDARY OBJECTIVES:
I. To perform a preliminary exploratory assessment of whether probability of detectable
tumor shrinkage/response correlates with pre RO4929097 presence in tumor of an activating
epidermal growth factor receptor (EGFR) mutation, the T790M EGFR mutation, met
proto-oncogene (c-MET) gene amplification or insulin-like growth factor 1 receptor (IGF-1R)
expression or activation or various Notch pathway markers. (Dose escalation portion) II. To
perform a preliminary exploratory assessment of whether addition of RO4929097 to erlotinib
leads to tumor shrinkage/response in any tumor deposits that had previously exhibited growth
on erlotinib alone. (Dose escalation portion) III. Conduct a preliminary exploratory
assessment on the expansion cohort with respect to tumor shrinkage/response of the following
over the first 2 cycles of erlotinib and RO4929097 treatment with and without the presence
of mutation, amplification, and activation of markers: tumor IHC scores and RPPA expression
of the Notch ligand jagged 1 (Jag1), and the Notch targets hairy and enhancer of split 1
(HES1), hairy/enhancer-of-split related with YRPW motif protein 1 (HEY1); tumor IHC scores
and RPPA expression of putative stem cell markers cluster of differentiation (CD)24
(decreased in stem cells), CD44, CD133, dehydrogenase and of the epithelial to mesenchymal
transition (EMT) markers E-cadherin and vimentin; detectability in tumor of EGFR T790M
mutations, MET amplification, and IGF-1R expression and activation; and soluble markers of
angiogenesis, including stromal cell-derived factor 1 alpha (SDF-1alpha), basic fibroblastic
growth factor (bFGF), cryptic epitope of collagen IV, interleukin (IL)-6, IL-8, vascular
endothelial growth factor (VEGF). (Expansion cohort) IV. Conduct a preliminary exploratory
assessment of whether percent tumor shrinkage/response or time to progression correlates
with pre-therapy IHC and RPPA expression of Notch 1, 2, 3 and 4, the above Notch pathway and
stem cell markers, with baseline detectability of T790M mutations and MET amplification, and
with baseline IGF-1R expression and activation, and with change in these markers from the
initial biopsy to the subsequent biopsy. (Expansion cohort) V. In tumor samples collected
both during the dose escalation phase and in the expansion cohort, assess if IHC and RPPA
expression of Notch, Notch ligand and Notch targets correlates with expression of stem cell
markers.
VI. Assess if percent tumor shrinkage/response, time to progression and baseline and change
in IHC and RPPA expression of Notch, Notch ligand, Notch targets and stem cell markers
varies with: tumor Notch gene amplification as assessed by fluorescent in situ hybridization
(FISH); tumor IHC and RPPA expression of selected members of the Wnt and Hedgehog pathways
(since these could lead to stem cell properties in cells that do not express Notch); host
(peripheral blood mononuclear cell) polymorphisms for relevant genes in the Notch pathway;
tumor micro ribonucleic acid (RNA) levels.
VII. Trough levels of erlotinib and RO4929097 will be measured in plasma samples of all
patients on the dose-escalation portion of the study approximately 24 hours after the cycle
1, day 1 dose and again approximately 24 hours after the cycle 2, day 1 dose. These
measurements are being done to permit a preliminary exploratory assessment of whether there
is induction of metabolism of one or both drugs that will lead to decreased drug plasma
concentrations.
VIII. In the Expansion Cohort, plasma levels of erlotinib and RO4929097 will be measured
approximately 24 hours after the cycle 2, day 21 erlotinib dose (just prior to initiation of
cycle 3), and plasma levels of both agents will be measured in plasma approximately 24 hours
after the cycle 3, day 1 doses of both agents. These measurements are done to permit a
preliminary exploratory assessment of whether: plasma drug levels correlate with % tumor
shrinkage/response or with change in tumor biomarkers over the first 6 weeks of therapy;
erlotinib plasma concentrations are affected by RO4929097 administration.
OUTLINE: This is a dose-escalation study.
Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-21 and
gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and
15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable
toxicity.
After completion of study treatment, patients are followed up for 12 weeks.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01664754 -
Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT02451930 -
A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
|
Phase 1 | |
Withdrawn |
NCT02106559 -
Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy
|
N/A | |
Completed |
NCT02364609 -
Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
|
Phase 1 | |
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT01935336 -
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
|
Phase 2 | |
Withdrawn |
NCT01971489 -
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01839955 -
Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer
|
Phase 1 | |
Terminated |
NCT01193868 -
RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy
|
Phase 2 | |
Completed |
NCT00963807 -
Trial Comparing the Use of FLT PET to Standard CT to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable NSCLC
|
Phase 2 | |
Completed |
NCT00986674 -
Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00087412 -
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00085280 -
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00052338 -
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT00006929 -
Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT02879994 -
Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT03305380 -
Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth
|
||
Completed |
NCT02728596 -
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
|
N/A | |
Completed |
NCT02858869 -
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
|
Phase 1 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 |